The Central Protocol and Data Monitoring Office (CPDMO) within the St. Jude Comprehensive Cancer Center (SJCCC) provides centralized, administrative, regulatory and educational services to SJCCC members for the conduct of clinical trials-related activities. It is the main coordinating center for protocol development, regulatory and compliance guidance, administrative submissions, protocol registration data, and quality assurance, including monitoring. The overarching goal of the CPDMO is to provide outstanding clinical trials support to SJCCC clinical investigators by: (1) facilitating the development of high quality clinical research trials, within a standardized frame work of trial development and content, so that all appropriate institutional and Federal requirements are met prior to accruing participants; (2) maintaining a centralized submission process for institutional review and approval (CT-SRC and the IRB); (3) ensuring appropriate standards of clinical trials across the institution by encouraging consistent trial conduct and regulatory compliance through the monitoring of trials; (4) ensuring appropriate research participant enrollment via a centralized clinical trial registration system; (5) providing appropriate infrastructure and coordination for clinical trials at our affiliate and collaborating institutions; and (6) adhering to the Data Safety Monitoring Plan approved by the NCI in August 2010. In addition, the CPDMO provides administrative support to the CTSRC to ensure appropriate scientific review of all clinical trials at the SJCCC. Clinical trials are monitored commensurate with the degree of risk involved in study subject participation, as well as the size and complexity of the study. Our position is that trial monitoring and safety reporting is a shared responsibility across all members in the clinical trial process, each having different roles and responsibilities (the Institution and the Principal Investigators and study team(s), oversight committees, monitors, etc.). Particular attention is paid to monitoring investigator-initiated clinical trials, especially those for which there is no independent outside monitoring program.

Public Health Relevance

The overall goals of the CPDMO and the Data and Safety Monitoring Plan are to support Cancer Center clinical investigators, and to provide an environment conducive to maintaining the highest standards and measures in clinical research and data integrity while upholding the safety and well-being of our trial participants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-39
Application #
9439727
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Hazlitt, Robert A; Min, Jaeki; Zuo, Jian (2018) Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss. J Med Chem 61:5512-5524
Hoehn, Mary Ellen; Calderwood, Julie; Gannon, Edwin et al. (2018) Ocular complications in a young pediatric population following bone marrow transplantation. J AAPOS 22:102-106.e1
Devine, Katie A; Mertens, Ann C; Whitton, John A et al. (2018) Factors associated with physical activity among adolescent and young adult survivors of early childhood cancer: A report from the childhood cancer survivor study (CCSS). Psychooncology 27:613-619
Matreyek, Kenneth A; Starita, Lea M; Stephany, Jason J et al. (2018) Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat Genet 50:874-882
Li, Yanfeng; Bakke, Jesse; Finkelstein, David et al. (2018) HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. Oncogenesis 7:9
Khan, Raja B; Merchant, Thomas E; Sadighi, Zsila S et al. (2018) Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. J Neurooncol 136:379-384
Zimmerman, Mark W; Liu, Yu; He, Shuning et al. (2018) MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discov 8:320-335
Hammill, Jared T; Bhasin, Deepak; Scott, Daniel C et al. (2018) Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem 61:2694-2706
Stewart, Daniel P; Marada, Suresh; Bodeen, William J et al. (2018) Cleavage activates dispatched for Sonic Hedgehog ligand release. Elife 7:
Browne, Emily K; Zhou, Yinmei; Chemaitilly, Wassim et al. (2018) Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia. Cancer 124:4248-4259

Showing the most recent 10 out of 6764 publications